Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
19 studies found for:    ponatinib
Show Display Options
Rank Status Study
1 Active, not recruiting Ponatinib - 2nd Line Therapy
Condition: Leukemia
Intervention: Drug: Ponatinib
2 Suspended Ponatinib for Squamous Cell Lung and Head and Neck Cancers
Condition: Non-Small Cell Lung Cancer, Head and Neck Cancer
Intervention: Drug: ponatinib
3 Recruiting Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Condition: Leukemia
Intervention: Drug: Ponatinib
4 Not yet recruiting Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Condition: Endometrial Neoplasms
Intervention: Drug: Ponatinib
5 Active, not recruiting A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions: Drug: ponatinib - Phase 1;   Drug: ponatinib - Phase 2
6 Recruiting Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Conditions: Adenocarcinoma of the Lung;   Extensive Stage Small Cell Lung Cancer;   Limited Stage Small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Ponatinib
7 Approved for marketing Expanded Access Program of Ponatinib
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: ponatinib
8 Not yet recruiting Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Conditions: Advanced Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage II Gallbladder Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
9 Not yet recruiting Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations
Condition: Malignant Neoplasm
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
10 Active, not recruiting PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Ph+ Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Ponatinib (AP24534)
11 Recruiting Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF  (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
12 Recruiting Ponatinib in Advanced NSCLC w/ RET Translocations
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ponatinib
13 Active, not recruiting A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: GIST
Intervention: Drug: ponatinib
14 Not yet recruiting Phase II Front-line Treatment of Adult Affected of Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (ALL) With Ponatinib.
Conditions: Philadelphia Positive;   BCR-ABL Positive;   Acute Lymphoblastic Leukemia
Intervention: Drug: Ponatinib
15 No longer available Compassionate Use Ponatinib
Conditions: Philadelphia Chromosome Positive (Ph+) Leukemias;   Chronic Myeloid Leukemia
Intervention: Drug: Ponatinib
16 Recruiting Ponatinib for Advanced Medullary Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention: Drug: Ponatinib
17 Terminated
Has Results
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib;   Drug: imatinib (Gleevec/ Glivec)
18 Active, not recruiting Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Conditions: Chronic Myelogenous Leukemia;   Hematologic Malignancies
Intervention: Drug: Ponatinib, AP24534
19 Recruiting Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia
Interventions: Device: in vitro kinase inhibitor assay;   Drug: Sunitinib;   Drug: Dasatinib;   Drug: Nilotinib;   Drug: Sorafenib;   Drug: Ponatinib

Indicates status has not been verified in more than two years